Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies [Benzinga]
Tuesday, October 8, 2024 1 min read
Key Takeaway: Enveric Biosciences is exploring a novel approach to psychedelics by developing non-hallucinogenic versions that may act similarly to antidepressants. CEO Joseph Tucker emphasizes that these therapies could offer relief without requiring extensive in-clinic sessions, marking a significant shift in treatment methodologies for mental health.
Price reaction · baseline $76.5 (2024-10-07 close) · hit pre-market · clean, no other ENVB news in the window
day 0 close · peak
-2.4%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric is innovating in the psychedelics space.
Potential for non-hallucinogenic therapies to provide relief.
Could reduce the need for extensive in-clinic sessions.
Full Press Release Details
Companies like Enveric Biosciences are taking a different approach by attempting to strip psychedelics of their hallucinogenic effects altogether. Enveric’s CEO Joseph Tucker suggests that a non-hallucinogenic version of psychedelics, if effective, could function much like an antidepressant, providing relief without the need for extensive in-clinic sessions.
Full Article >>
Frequently Asked Questions
What is Enveric Biosciences exploring?
Enveric Biosciences is developing non-hallucinogenic versions of psychedelics.
How could non-hallucinogenic psychedelics help patients?
They may provide relief similar to antidepressants without extensive in-clinic sessions.
Who is the CEO of Enveric Biosciences?
The CEO of Enveric Biosciences is Joseph Tucker.
What is the goal of Enveric's new approach?
The goal is to strip psychedelics of their hallucinogenic effects for safer therapies.